Deerfield Mgmt III, L.P.'s Net Worth

$156 Million

Who is Deerfield Mgmt III, L.P.?

Deerfield Mgmt III, L.P. has an estimated net worth of $156 Million. This is based on reported shares across multiple companies, which include Fractyl Health, Inc., RHYTHM PHARMACEUTICALS, INC., XERIS PHARMACEUTICALS INC, REGENXBIO Inc., Editas Medicine, Inc., Shockwave Medical, Inc., AERIE PHARMACEUTICALS INC, ARVINAS INC., Neos Therapeutics, Inc., Avalanche Biotechnologies, Inc., GRAYBUG VISION, INC., Acutus Medical, Inc., Larimar Therapeutics, Inc., Syros Pharmaceuticals, Inc., CytomX Therapeutics, Inc., PROTEON THERAPEUTICS INC, AveXis, Inc., SteadyMed Ltd., aTYR PHARMA INC, LUMOS PHARMA, INC., ALIMERA SCIENCES INC, Homology Medicines, Inc., Oncorus, Inc., Audentes Therapeutics, Inc., and ARS Pharmaceuticals, Inc..

SEC CIK

Deerfield Mgmt III, L.P.'s CIK is 0001610540

Past Insider Trading and Trends

2015 was Deerfield Mgmt III, L.P.'s most active year for acquiring shares with 65 total transactions. Deerfield Mgmt III, L.P.'s most active month to acquire stocks was the month of September. 2022 was Deerfield Mgmt III, L.P.'s most active year for disposing of shares, totalling 33 transactions. Deerfield Mgmt III, L.P.'s most active month to dispose stocks was the month of November. 2020 saw Deerfield Mgmt III, L.P. paying a total of $67,000,000.00 for 12,487,161 shares, this is the most they've acquired in one year. In 2020 Deerfield Mgmt III, L.P. cashed out on 59,843,941 shares for a total of $18,052,380.80, their largest year based on trade value.